{"id":308,"date":"2014-07-28T08:26:58","date_gmt":"2014-07-28T08:26:58","guid":{"rendered":"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/?p=308"},"modified":"2014-07-28T08:26:58","modified_gmt":"2014-07-28T08:26:58","slug":"waters-corporation-acquires-iknife-technology","status":"publish","type":"post","link":"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/2014\/07\/28\/waters-corporation-acquires-iknife-technology\/","title":{"rendered":"Waters Corporation acquires iKnife technology"},"content":{"rendered":"<p><a href=\"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/files\/2014\/07\/IKnife2.jpg\"><img loading=\"lazy\" decoding=\"async\" width=\"300\" height=\"207\" class=\"alignleft size-medium wp-image-309\" src=\"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/files\/2014\/07\/IKnife2-300x207.jpg\" alt=\"IKnife2\" \/><\/a><\/p>\n<p>Waters, a leading analytical instrument manufacturer, announced this week that it acquired the technology, called Rapid Evaporative Ionisation Mass Spectrometry (REIMS), from MediMass Ltd, a company created by the iKnife\u2019s inventor, CSM\u2019s <a href=\"http:\/\/www.imperial.ac.uk\/AP\/faces\/pages\/read\/Home.jsp?person=z.takats&amp;_adf.ctrl-state=b8dltly91_3&amp;_afrRedirect=1718180440125198\">Professor Zoltan Takats<\/a>.<\/p>\n<p>For the past three years, Waters and MediMass have worked in partnership with researchers at Imperial to investigate applications of REIMS in surgery, which could potentially provide surgeons with diagnostic information about the tissue they are cutting in real time. <a href=\"http:\/\/www3.imperial.ac.uk\/newsandeventspggrp\/imperialcollege\/newssummary\/news_25-7-2014-14-54-19\">Read more<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Waters, a leading analytical instrument manufacturer, announced this week that it acquired the technology, called Rapid Evaporative Ionisation Mass Spectrometry (REIMS), from MediMass Ltd, a company created by the iKnife\u2019s inventor, CSM\u2019s Professor Zoltan Takats. For the past three years, Waters and MediMass have worked in partnership with researchers at Imperial to investigate applications of [&hellip;]<\/p>\n","protected":false},"author":710,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-308","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/wp-json\/wp\/v2\/posts\/308","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/wp-json\/wp\/v2\/users\/710"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/wp-json\/wp\/v2\/comments?post=308"}],"version-history":[{"count":5,"href":"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/wp-json\/wp\/v2\/posts\/308\/revisions"}],"predecessor-version":[{"id":314,"href":"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/wp-json\/wp\/v2\/posts\/308\/revisions\/314"}],"wp:attachment":[{"href":"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/wp-json\/wp\/v2\/media?parent=308"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/wp-json\/wp\/v2\/categories?post=308"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs-staging.imperial.ac.uk\/surgeryandcancer\/wp-json\/wp\/v2\/tags?post=308"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}